Participant blinding and gastrointestinal illness in a randomized, controlled trial of an in-home drinking water intervention
- PMID: 11749745
- PMCID: PMC2730258
- DOI: 10.3201/eid0801.001481
Participant blinding and gastrointestinal illness in a randomized, controlled trial of an in-home drinking water intervention
Abstract
We conducted a randomized, triple-blinded home drinking water intervention trial to determine if a large study could be undertaken while successfully blinding participants. Households were randomized 50:50 to use externally identical active or sham treatment devices. We measured the effectiveness of blinding of participants by using a published blinding index in which values >0.5 indicate successful blinding. The principal health outcome measured was "highly credible gastrointestinal illness" (HCGI). Participants (n=236) from 77 households were successfully blinded to their treatment assignment. At the end of the study, the blinding index was 0.64 (95% confidence interval 0.51-0.78). There were 103 episodes of HCGI during 10,790 person-days at risk in the sham group and 82 episodes during 11,380 person-days at risk in the active treatment group. The incidence rate ratio of disease (adjusted for the clustered sampling) was 1.32 (95% CI 0.75, 2.33) and the attributable risk was 0.24 (95% CI -0.33, 0.57). These data confirm that participants can be successfully blinded to treatment group assignment during a randomized trial of an in-home drinking water intervention.
References
-
- Payment P, Siemiatycki J, Richardson L, Gilles R, Franco E, Prevost M. A prospective epidemiological study of gastrointestinal health effects due to the consumption of drinking water. Int J Environ Health Res. 1997;7:5–31. 10.1080/09603129773977 - DOI
-
- Safe Drinking Water Act: Amendments of 1996. Washington, D.C.: United States Congress; 1996.
-
- Donner A, Birkett N, Buck C. Randomization by cluster: Sample size requirements and analysis. Am J Epidemiol. 1981;114:906–14. - PubMed